Copyright © 2021 Pharmascimed. All Rights Reserved.
hypereosinophlia
- Home
- hypereosinophlia
AZ’s Fasenra granted FDA Orphan Drug Designation
- February 7, 2019
- 0
The U.S. FDA has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome. The designation comes on the back of data from a phase II trial conducted...
Read moreTrending
Recent Posts
The coming age of biosimilars
- February 26, 2019
- 0
Novartis acquires game-changing cardiovascular therapy
- February 25, 2019
- 0
Roche buys gene therapy company Spark for $4.3bn
- February 25, 2019
- 0
AbbVie and Voyager Therapeutics in Parkinson’s Pact
- February 22, 2019
- 0